J&J Petitions Supreme Court On Pre-emption, ‘Clear Evidence’ In OTC Litigation
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson files a writ of certiorari asking the Supreme Court to review a $140m judgment against the firm in Massachusetts. Questions over “clear evidence” needed for FDA decision to pre-empt state courts are at heart of issue and need the court’s consideration.
You may also be interested in...
Another Motrin Failure-To-Warn Decision Rejects Pre-emption Defense
Massachusetts’ supreme court says no “clear evidence” showed “FDA would not have approved a warning on OTC ibuprofen labels stating that redness, rash, and blisters may lead to a life-threatening disease.” McNeil’s failed appeal of a verdict in Children’s Motrin litigation adds to rulings that reject federal pre-emption against failure-to-warn complaints.
Decision For McNeil In Children's Motrin Suit Notes Limits Of OTC Labeling
A federal court ruling cautions that drugs should not be expected to have labels that "guarantee against every conceivable adverse consequence.
High Court’s Wyeth v. Levine Ruling Returns Pre-Emption Status Quo
The Supreme Court's ruling in Wyeth v. Levine dashes pharmaceutical industry hopes for broad protection from state product liability lawsuits, but is not expected to trigger a sea-change in current industry operations